Semenya Misses Tokyo, May be Forced out of Olympics for Good

This could be it for Caster Semenya and the Olympics.

Forced out of her favorite race by World Athletics’ testosterone rules, the two-time Olympic champion in the 800 meters took a late shot at qualifying for Tokyo in the 5,000 meters, an event not affected by the hormone regulations. She came up short.

Now 30, Semenya’s hopes of making it back to the Olympics are dwindling.

The South African once said she wanted to run at top track events until she was 40.

Now, her future ambitions depend on a final, long-shot legal appeal of the testosterone rules or transforming from the world’s dominant middle-distance runner into a successful long-distance athlete. That’s going to be hard for her.

Semenya is the athlete that has perhaps stoked the most controversy in track and field over the last decade. If there are no more appearances on the biggest stage, it’s been a career like no other. In 12 years at the top, Semenya has won two Olympic golds and three world championship titles, but her success has come amid near-constant interference by track authorities. She has only competed free of restrictions of one type or another for three of those 12 years.

Why can’t Semenya defend her 800 title in Tokyo

In 2018, world track and field’s governing body introduced rules it said were aimed at female athletes with conditions called differences of sex development, or DSDs. The key for World Athletics is that these athletes have testosterone levels that are higher than the typical female range. The track body argues that gives them an unfair advantage. Semenya is the highest-profile athlete affected by the regulations, but not the only one.

The rules demand that Semenya lower her testosterone levels artificially — by either taking birth control pills daily, having hormone-blocking injections or undergoing surgery — to be allowed to run in races from 400 meters to one mile. Semenya has simply refused to do that, pointing out the irony that in a sport where doping is such a scourge, authorities want her to take drugs to be eligible to run at the Olympics.

“Why will I take drugs?” Semenya said in 2019. “I’m a pure athlete. I don’t cheat. They should focus on doping, not us.”

But she can run the 5,000?

Yes. Strangely, World Athletics decided to only enforce the testosterone rules for track events from 400 meters to one mile, raising criticism from Semenya’s camp that the regulations were specifically designed to target her because of her dominance.

It means Semenya can compete in the 100 and 200 meters and long-distance races without lowering her testosterone levels. Field events are also unregulated. After a brief go at 200 meters, Semenya attempted to qualify for Tokyo in the 5,000 meters, running races in Pretoria and Durban in South Africa and, most recently, at international meets in Germany and Belgium last month. She never came within 20 seconds of the Olympic qualifying mark.

The court battle

Semenya continues to fight against the testosterone regulations in court. She has launched three legal appeals against the rules, calling them unfair and discriminatory, and appears determined to wage her legal fight to the very end. Having failed in appeals at the Court of Arbitration for Sport and the Swiss supreme court, Semenya has now lodged an appeal with the European Court of Human Rights.

Semenya’s first appeal at sport’s highest court revealed a bitter battle between her and track authorities, centered on World Athletics’ claim in the closed-doors hearing that she was “biologically male.” Semenya angrily refuted that, having been identified as female at birth and having identified as female her whole life. She called the assertion “deeply hurtful.”

Other athletes affected

The issue won’t disappear with Semenya. Just this week, two 18-year-old female athletes from Namibia were barred from competing in the 400 meters at the Tokyo Olympics after they underwent medical tests and it was discovered they had high natural testosterone levels. One of them, Christine Mboma, is the world under-20 record holder.

The two runners that finished second and third behind Semenya at the 2016 Olympics, Francine Niyonsaba of Burundi and Margaret Wambui of Kenya, have said publicly they also are affected by the testosterone regulations and have been banned from the 800, too, unless they undergo medical intervention. Niyonsaba has qualified for the Olympics in the 5,000 meters.

What now?

Semenya has been clear that the rules won’t force her out of track and she’ll keep running and keep enjoying the sport, even if she can’t go to the biggest events.

“Now is all about having fun,” she said at a meet in South Africa in April. “We’ve achieved everything that we wanted‚ all the major titles‚ inspiring the youth.”

“For me, it’s not about being at the Olympics,” she said. “It’s being healthy and running good times and being in the field for the longest.”

Source: Voice of America

UN, African Union Peacekeepers Hand Over 14 Darfur Bases to Sudan

Fourteen bases that had been run jointly by the United Nations and the African Union in Sudan’s Darfur region for 13 years are now under Sudan’s control and to be used by local populations.

The recent official handover comes in accordance with a framework agreement signed on March 4 between the United Nations and African Union Mission in Darfur (UNAMID) and Sudan.

The U.N. Security Council voted last year to turn over the sites to the Sudanese government, but M’Baye Babacar Cissé, U.N. assistant secretary-general, said the repatriation of equipment and staff from Darfur had been going on for four months.

“The main beneficiaries in fact were the local communities and the IDPs (internally displaced persons) and the teams’ sites were supposed to be used as vocational training centers, education centers, clinics, health centers or community activity centers,” Babacar told VOA’s South Sudan in Focus program.

Eight of the 14 sites were stripped bare by looters from the local communities in Darfur. But some of the sites are serving locals, Babacar said, referencing the former outposts known as Zalenji and Kalma.

Zalenji “is now [under] the University of Zalenji,” where early occupation of the sites by the university of the same name prevented looting, he said.

“… Kalma was transferred to the IDPs and now they are the ones managing Kalma as [a] health center,” Babacar told VOA.

UNAMID repatriated its peacekeeping equipment to its respective countries along with about 6,000 staff members who had performed peacekeeping operations in Darfur since December 2020. Some of those operations, however, were interrupted by the COVID-19 pandemic, Babacar said.

“We had at the end of December 2020 programmatic activities as well as state liaison projects that were implemented by the U.N. agencies that were not completed because of the COVID crises that affected the operation.”

The pandemic interrupted some community projects that were directly under the supervision of Civil Affairs of UNAMID, including water projects and community engagement workshops with youth, women and local traditional leaders.

The U.N. diplomat said Sudan’s transitional government now has the responsibility of protecting civilians against attacks in Darfur.

“The government is committed to putting together a joint force to protect the local community and the U.N. will continue to support that end, but we will no longer have a physical protection mandate,” Babacar told VOA.

During UNAMID’s 13-year mandate, it had more than 97,000 peacekeepers including military and police in Darfur, drawn from 110 countries. It will leave behind a small contingent estimated to be 1,000 to 1,500 individuals.

Hundreds of people have been killed or wounded this year in Darfur, an area plagued by deadly violence for decades during the administration of former President Omar al Bashir.

Dozens of people were killed in January shortly after the peacekeepers announced their phased withdrawal from the region. Arab militias attacked a displacement camp in El Geneina, the capital of West Darfur. Five days of fighting between Arab and Masalit tribesmen in April left 87 people dead and more than 190 people wounded, according to the Sudanese Doctors Committee in West Darfur.

Source: Voice of America

WHO Calls for Urgent Action to Slow COVID-19 Spread in Africa

The World Health Organization is calling for urgent action to stem the rapid spread of COVID-19 across Africa, which is being fueled by a surge of more contagious variants of the disease.

Latest reports say COVID-19 cases in Africa have been rising by 25% every week for the past six weeks, bringing reported cases there to more than 5.4 million, including 141,000 deaths.

WHO regional director for Africa, Matshidiso Moeti, warns the rampant spread of the more contagious alpha, beta, and delta variants is raising the pandemic threat across the continent to a new level.

“The speed and scale of Africa’s third wave is like nothing we have seen before,” said Moeti. “Cases are doubling every three weeks, compared to every four weeks at the start of the second wave. Almost 202,000 cases were reported in the past week and the continent is on the verge of exceeding its worst week ever in this pandemic.”

In the same period, WHO reports deaths have risen by 15% across 38 African countries to nearly 3,000. The jump is largely due to the highly transmissible coronavirus variants, which have spread to dozens of countries. The most contagious delta variant has been found in 16 countries. It reportedly has become the dominant strain in South Africa.

Moeti says more people are falling ill and requiring hospitalization, even people younger than 45 years. She says evidence is growing that the delta variant is causing longer and more severe illness.

With Africa’s lack of life-saving vaccines, Moeti says it is important for people to practice public health measures, such as wearing masks, social distancing, and frequent handwashing to prevent the disease from spreading.

“With WHO’s guidance, countries are taking action to curb the rise in cases,” said Moeti. “All countries in resurgence in the region have put limits on people gathering to help with physical distancing. …They are using nuanced, risk-based approaches, informed by the local epidemiology, in an effort to avoid nationwide lockdowns that we know cause great harm to livelihoods, particularly for low-income households.”

Vaccines are proving highly effective against the COVID-19 variants and in ending devastating surges of severe cases of the disease. They are widely available in the world’s richest countries, but not Africa.

Moeti is urgently appealing to countries to share their excess doses to help plug the continent’s vaccine gap, saying Africa must not be left languishing in the throes of its worst wave yet.

Source: Voice of America

At Least 43 Migrants Drown in Shipwreck off Tunisia, Red Crescent Says

At least 43 migrants drowned in a shipwreck off Tunisia as they tried to cross the Mediterranean from Libya to Italy, while another 84 were rescued, humanitarian organization the Tunisian Red Crescent told Reuters on Saturday.

The boat that set off from Zuwara, on Libya’s northwest coast, included migrants from Egypt, Sudan, Eritrea and Bangladesh.

Source: Voice of America

Swim Caps for Thick, Curly Hair Not Allowed at Olympics

Swimming caps designed for natural Black hair won’t be allowed at the upcoming Tokyo Olympics, with the sport’s world governing body saying they are unsuitable due to them not “following the natural form of the head.”

The British brand Soul Cap sought to have its products officially recognized by FINA, the federation that administers international competitions in water sports, but its application submitted last year was rejected. The company makes extra-large caps designed to protect thick, curly, and voluminous hair.

The caps were barred by FINA on the grounds that to their “best knowledge, the athletes competing at the international events never used, neither require to use, caps of such size and configuration.”

FINA described the swim caps as unsuitable due to them not “following the natural form of the head.”

The Switzerland-based governing body said Friday that it is currently reviewing the situation with Soul Cap and similar products while “understanding the importance of inclusivity and representation.”

FINA said in the statement that it is committed to ensuring all aquatics athletes have access to appropriate swimwear for competition as long as such swimwear doesn’t provide a competitive advantage.

“We don’t see this as a setback, but a chance to open up a dialogue to make a bigger difference in aquatics,” Soul Cap cofounders Toks Ahmed-Salawudeen and Michael Chapman tweeted. “A huge thanks to all who have supported us and our work so far.”

The men founded the company in 2017 after meeting a woman with natural Black hair who struggled with her swim cap. According to the company’s website, it has shipped over 30,000 swim caps to customers worldwide.

“For younger swimmers, feeling included and seeing yourself in a sport at a young age is crucial,” Ahmed-Salawudeen said in an online post. “There’s only so much grassroots and small brands can do — we need the top to be receptive to positive change.”

Alice Dearing, who will compete in marathon swimming in Tokyo as the only Black swimmer for Britain, endorses the company’s caps.

“People used to tell me my hair was ‘too big’ for the cap — never that the cap was too small for my hair,” she said in a blog post on the company’s website.

FINA pointed out Friday that there is no restriction on Soul Cap usage for recreational and teaching purposes. It said it appreciates the efforts of the company and other suppliers in making sure people have a chance to enjoy the water.

FINA said it would speak with Soul Cap officials about using the company’s products at its development centers located in Dakar, Senegal, and Kazan, Russia.

Source: Voice of America

Parexel to be Acquired by EQT Private Equity and Goldman Sachs Asset Management

BOSTON and DURHAM, N.C., July 02, 2021 (GLOBE NEWSWIRE) — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund (“EQT Private Equity”) and the Private Equity business within Goldman Sachs Asset Management (“Goldman Sachs”) from Pamplona Capital Management LP for $8.5 billion.

“Over the past 18 months Parexel has continued its strong growth trajectory delivering on its patients-first focus and accelerating new therapies to patients in need around the world,” said Parexel CEO Jamie Macdonald. “With the market for outsourced clinical research services anticipated to grow at a conservative CAGR of 8 to 9 percent, our focus remains on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape. EQT and Goldman Sachs support this vision and are committed to investing in Parexel and our people to capitalize on this exciting market opportunity and make a difference for patients.”

Eric Liu, Partner and Global Co-Head of Healthcare at EQT, commented, “We have followed Parexel closely during the past few years and have been impressed by the company’s development and trajectory. Our investment in Parexel reflects EQT’s thematic focus on the life sciences industry, as well as our commitment to partner with businesses that have a positive impact on society. We are excited to partner with Goldman Sachs for the next stage of Parexel’s journey, and to back Jamie, who prior to his role at Parexel had been a long-time senior advisor to EQT, as well as the rest of the Parexel team.”

Jo Natauri, Partner and Global Head of Private Healthcare Investing within Goldman Sachs Asset Management, commented, “We are thrilled to partner with Jamie Macdonald, the entire Parexel management team and EQT to support Parexel, which has a distinguished track record of delivering clinical excellence to their large pharma and biotech customers globally. We believe this investment will accelerate Parexel’s growth as it builds on the company’s global footprint, strong operational capabilities and expansive healthcare network.”

John Halsted, Managing Partner, Pamplona Capital Management, commented, “We’re very proud of Parexel’s progress over the past four years and the important work they do in helping bring exciting new therapies to patients in need. In particular, they successfully adapted the business to work in the midst of a global pandemic, and supported the development of therapies to combat the COVID-19 pandemic itself. We wish them every success in their next phase of growth.”

“We have enjoyed our partnership with Pamplona, and thank them for their leadership and support in helping to transform Parexel under their ownership,” concluded Mr. Macdonald. “Over the past months, our ability to pivot and adapt have fostered new ways of working while developing a strong track record of quality and delivery for customers around the world. As we continue in this new era of clinical development and focus aggressively on meeting our customers’ needs for innovation in such areas as Real World Evidence, Decentralized Clinical Trials, Biostatistics and Data Management — and in key regions such as Asia/Pacific where we’re among the largest and longest-tenured CROs — we’re excited to be partnering with EQT and Goldman Sachs. We look forward to benefitting from their strong industry experience and to further accelerating Parexel as one of the world’s leading and fastest-growing CROs.”

The transaction is subject to customary conditions, including receipt of applicable regulatory approvals. Evercore acted as the financial advisor to Parexel, and Kirkland & Ellis LLP provided legal counsel in connection with the transaction. Goldman Sachs and Jefferies LLC acted as financial advisors to EQT Private Equity and Goldman Sachs Asset Management, and Simpson Thacher & Bartlett LLP provided legal counsel in connection with the transaction.

About Parexel
Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services to leveraging real world insights, our therapeutic, technical, and functional ability is underpinned by a deep conviction in what we do. Parexel was named “Best Contract Research Organization” in December 2020 by an independent panel for Informa Pharma Intelligence. For more information, visit parexel.com and follow us on LinkedInTwitter, and Instagram.

About EQT
EQT is a purpose-driven global investment organization with more than EUR 67 billion in assets under management across 26 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately EUR 29 billion and more than 175,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. For more information, visit www.eqtgroup.com or follow EQT on LinkedInTwitterYouTube and Instagram.

About Goldman Sachs Asset Management Private Equity
Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs (NYSE: GS), we deliver investment and advisory services for the world’s leading institutions, financial advisors and individuals, drawing from our deeply connected global network and tailored expert insights, across every region and market—overseeing more than $2 trillion in assets under supervision worldwide as of March 31, 2021. Driven by a passion for our clients’ performance, we seek to build long-term relationships based on conviction, sustainable outcomes, and shared success over time. Goldman Sachs Asset Management invests in the full spectrum of alternatives, including private equity, growth equity, private credit, real estate and infrastructure. Established in 1986, the Private Equity business within Goldman Sachs Asset Management has invested over $75 billion since inception. We combine our global network of relationships, our unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across our portfolios. Follow us on LinkedIn.

About Pamplona Capital Management
Pamplona Capital Management is a specialist investment manager established in 2005 that provides an alternative investment platform across private equity and other diversified strategies. With offices in New York, London, Madrid, and Malta, Pamplona manages over $11 billion in assets for a variety of clients including public pension funds, international wealth managers, multinational corporations, family offices, and funds of hedge funds. Pamplona invests long-term capital across the capital structure of its portfolio companies in both public and private market situations.

CONTACTS

For Parexel:
Lori Dorer
Senior Vice President, Corporate Communications
+1 513 496 8121

Lindsay LeCain
Real Chemistry
+ 1 508 259 9521

For EQT:
Daniel Yunger, Kekst CNC, + 1 917 574 8582
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

For Goldman Sachs:
Leslie Shribman
+1 212 902 5400

For Pamplona Capital Management:
Ed Orlebar, TB Cardew
ed.orlebar@tbcardew.com
+44 (0)7738724630

Nyxoah Announces Pricing of Nasdaq Public Offering

Mont-Saint-Guibert, Belgium – July 2, 2021, 2:40pm CET / 8:40am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the pricing of its initial public offering in the United States (the “Offering”) of 2,835,000 ordinary shares at a price to the public of US$ 30 per share for total gross proceeds of US$ 85.1 million before deducting underwriting discounts and commissions and estimated offering expenses.

In addition, Nyxoah has granted the underwriters a 30-day option to purchase up to an additional 425,250 ordinary shares at the initial public offering price less underwriting discounts and commissions, to cover over-allotments, if any.

The closing of the Offering is expected to occur on July 7, 2021, subject to the satisfaction of customary closing conditions.

Nyxoah’s ordinary shares are listed on Euronext Brussels under the symbol “NYXH”. The ordinary shares are expected to begin trading on the NASDAQ Global Market on July 2, 2021 under the same symbol.

Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the offering. Degroof Petercam is acting as a co-manager.

A registration statement relating to the ordinary shares was filed with the Securities and Exchange Commission (“SEC”) and declared effective on June 30, 2021. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction.

The offering of ordinary shares was made only by means of a prospectus. When available, a copy of the final prospectus can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924; Stifel, Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022; email: prospectus@cantor.com.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the closing of the offering. Forward-looking statements are based on Nyxoah’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ. Forward-looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.

IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated. A listing prospectus will be prepared by Nyxoah in accordance with Article 3 of the Prospectus Regulation for the purpose of having the new ordinary shares, issued pursuant to the Offering or (as the case may be) the exercise by the underwriters of their 30-day option to purchase additional ordinary shares, admitted to trading on Euronext Brussels.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment

 

Philogen Announces R&D Program Update

Philogen Announces R&D Program Update

Fibromun shows activity in pretreated glioma and sarcoma patients; OncoFAP targets tumor lesions in cancer patients; a new product partnered with AbbVie entered clinical studies

Siena (Italy), 2 July, 2021 – (Globe Newswire) – Philogen S.p.A. (BIT:PHIL), a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to provide an update on three R&D programs: Fibromun, OncoFAP and ABBV-022. A full pipeline update will be made to the market on 28 September, 2021, in the Company’s Half Year results announcement.

Prof. Dr. Dario Neri, Co-Founder, Chief Executive Officer and Chief Scientific Officer of Philogen S.p.A., said: “We are extremely pleased to see that our technology has been delivering exciting product candidates of diverse nature, both by our partners such as AbbVie and under our ownership, across a variety of clinical trials. The early signs of activity support our ambition to bring innovative treatment options to patients with serious unmet medical need.”

Fibromun

Fibromun (L19TNF), wholly-owned by Philogen, is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). Recombinant TNF has so far been approved only for certain loco-regional clinical applications.

  • Promising interim survival benefits have been demonstrated in the European Phase I/II trial, investigating Fibromun as a monotherapy for the treatment of IDH wildtype WHO Grade III-IV High-Grade Glioma at first recurrence/relapse. Data on progression free survival at six months are being finalized, while the overall survival data will be consolidated by the end of 2021, with expected publication in a peer-reviewed scientific journal in 2022.
  • In the European Phase I/II trial, in which Fibromun is combined with lomustine for the treatment of Glioblastoma at first recurrence/relapse, a partial response has been observed already in the first patient treated in the study. The historical overall response rate for this patient population is 4.3% (Wick et al., J Clin Oncol 2010, 28,1168)
  • A Parallel Scientific Advice (PSA) with the European Medicines Agency and the US Food and Drug Administration has been completed in June 2021. The development plan for the treatment of glioblastoma and the proposed strategy for marketing authorization have been discussed and agreed with competent authorities. Philogen will follow the recommendations that were provided during the PSA.
  • In the European Phase II trial, in which Fibromun is combined with dacarbazine for the treatment of pretreated advanced/metastatic Soft Tissue Sarcoma (3rd line), the second patient treated in the study enjoyed a partial response. The historical overall response rate for this patient population is 4.0% (Garcia-del-Muro et al., J Clin Oncol 2011, 29,2528). After the run-in part of the trial, the trial progresses to a randomized part.
  • Fibromun is investigated in six clinical trials, of which five have a pivotal potential. In Soft Tissue Sarcoma, the European Phase III trial in 1st line and the Phase II trial in 3rd line are expected to read out by the end of 2023.

OncoFAP

OncoFAP is a small molecule radiotracer, wholly-owned by Philogen, with ultra-high affinity for Fibroblast Activation Protein (FAP). The product is suitable for the non-invasive detection of a variety of metastatic solid tumors, as FAP is overexpressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate, and pancreatic cancers, as well as in some soft tissue and bone sarcomas)

  • Clinicians from the Department of Nuclear Medicine at the University Hospital of Münster have employed a OncoFAP-based radionuclide conjugate (OncoFAP-68Ga) in clinical scanning of patients with various FAP-positive cancer types and have shown excellent tumor uptake in both primary and metastatic lesions with low uptake in healthy organs (including kidneys) after intravenous injection.
  • These clinical results also support the investigation of OncoFAP-177Lu for Radionuclide Ligand Therapy (RLT).
  • Philogen is currently planning international, exploratory, clinical trials to investigate OncoFAP in a variety of cancer indications. The results from these studies will provide the basis for a pivotal clinical program in selected cancer types.

ABBV-022

ABBV-022, a product out-licensed by Philogen to AbbVie, consists of an IL-22 payload fused to a targeting antibody. The cytokine, selectively delivered to the epithelial surface of damaged gut mucosa, promotes survival of intestinal stem cells, improves goblet cell function and epithelial barrier, thereby reducing inflammation.

  • ABBV-022 has started a Phase I clinical trial for the treatment of Ulcerative Colitis. The original collaboration between Philogen and AbbVie began in 2014.

About Philogen

Philogen is a Swiss-Italian clinical-stage biotechnology company listed on the Italian Stock Exchange. It is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com.

ForwardLooking Statements

The forward-looking statements contained in this press release may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding anticipated advancement of preclinical development efforts and initiation and progression of clinical trials; anticipated enrollment in and progression of Philogen’s clinical trials; the availability of data from clinical trials and preclinical studies; anticipated regulatory filings; the therapeutic potential of Philogen’s product candidates; Philogen’s ability to achieve planned milestones. Philogen may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Philogen’s and its partners’ abilities to meet other anticipated deadlines and milestones, also due to the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Philogen’s product candidates by Philogen or its partners; the risk that Philogen may not realize the intended benefits of its technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Philogen’s product candidates; risks related to Philogen’s ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market products; other factors which could cause our actual result to differ from those contained in the forward-looking statements, as also described in greater detail in the Risk Factors section in the prospectus drafted by Philogen and approved by Consob on February 17, 2021. Any forward-looking statements contained in this press release speak only as of the date hereof, and Philogen expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. The information and contents of this press release do not: (i) constitute an order or an offer to purchase or to sell financial products or financial services; (ii) relate to special investment goals or to the financial situation or particular requirements of specific users. All information presented, reports published, and opinions expressed are intended purely for information purposes, and do not constitute an offer for the conclusion of a contract or other legal transaction. In particular, the content of the press release is not to be understood as an invitation or recommendation to buy or sell securities of Philogen, or as an advertisement for securities of Philogen. Neither does it constitute an offer to participate in any other transaction, including (but not restricted to) trading in derivatives. The mere use of the website does not give rise to any contractual relationship of any kind between the user and Philogen. Philogen expressly draws your attention to the fact that its share price is subject to fluctuation, and that the future development of the share price cannot be derived either from the previous price history or from the information and content shown on this website. Results achieved in the past provide no guarantee in regard to the future development of the share price. Philogen provides no guarantee of any kind that the capital invested will increase in value or maintain its value. In light of these given risks, we strongly advise you to seek professional advice before making any investment decision. The material contained on the website does not relieve the user from having to make his own decisions. This press release may contain links to external websites of third parties (external links) the content of which is outside the sphere of influence of Philogen. Visiting and using such websites that are accessible via such links are subject to the conditions of the data protection policy of these websites and the liability of the respective operators. Philogen accepts no responsibility and offers no guarantee of any kind for the content or websites of third parties and gives no assurances of any kind in this regard. Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties and shall not be liable for the content or web pages of third parties which are linked to the Philogen website, or which display the Philogen website in frames.

Philogen contacts

Dr. Christian Lizak (Business Development), Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

christian.lizak@philogen.com, emanuele.puca@philogen.com

Consilium Strategic Communications contacts

Mary-Jane Elliott, Davide Salvi

Philogen@consilium-comms.com

Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer

SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations.

“We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world.”

“At present, the development of China’s emerging biopharma has entered its golden age, and Junshi Biosciences is a classic example of this vigorous growth,” said Mr. Wei Qian, CCO of Junshi Biosciences. “I feel excited and encouraged to join Junshi Biosciences in such a critical growth period. I also look forward to bringing more new drugs and indications to patients through competitive commercialization strategies.”

Prior to joining Junshi Biosciences, Mr. Qian served as Vice President, BUO1 at Roche China for over five years, where he was responsible for the successful commercial launch of two blockbuster cancer drugs for the treatment of HER2-positive breast cancer in China. From 2006 to 2016, Mr. Qian held a variety of senior positions at AstraZeneca in China, with his most recent position as Vice President of GAA Business Unit, covering gastrointestinal system, anesthesia and anti-infection.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Amlan International Grows Southeast Asia Team With Addition of Nguyen Hai as Commercial Manager For Vietnam

Nguyen Hai

Nguyen Hai, Commercial Manager for Vietnam, Amlan International

CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) — As part of its commitment to help producers meet the growing demand for animal protein in Southeast Asia, Amlan International has named Nguyen Hai as the new commercial manager for Vietnam. Nguyen will lead the sales support and strategy in the country for Amlan, a global leader in mineral-based feed additives that promote the intestinal health of poultry and livestock and improve the economics of production.

Rising incomes in Vietnam are resulting in a growing demand for animal protein. Yearly poultry consumption per person in Vietnam was 13 kg in 2017 and is expected to rise to 17 kg by 2027, according to a report by the United Nation’s Food and Agriculture Organization (FAO). Export of meat and egg products in the country is projected to increase as improvements in production efficiency are helping poultry and swine operations meet the growing demand.

“Significant advancements are being made in natural feed additives to help producers in Vietnam and throughout Southeast Asia meet changing consumer preferences and adapt to increasing restrictions on the use of antibiotic growth promoters (AGPs) in animal protein production,” says Fred Kao, Vice President of Global Sales, Amlan International. “Nguyen will be a strong asset for the Southeast Asia team as we continue to work with the industry to deliver innovative, natural mineral-based feed additive solutions that producers can incorporate in their production strategies for long-term value and profitability.”

In his new role at Amlan, Nguyen will build and lead a technical team in providing superior sales and technical support to producers and industry stakeholders to drive greater efficiencies in poultry and swine production in Vietnam. Prior to joining Amlan, he was national sales manager for a prominent animal health company, where he led the sales and marketing strategy for Vietnam. While there, he managed budgets, led a sales team and increased target sales volume for two consecutive years.

Nguyen holds a master’s degree in animal science from the Asia Institute of Technology and a Ph.D. in animal science, with an emphasis in swine and piglet nutrition, from Queensland University.
“Shifting consumer trends and growing economies in Southeast Asia are requiring necessary improvements in animal protein production systems. Amlan is at the forefront of developing and introducing natural mineral-based feed additive solutions to drive success for producers in meeting that demand,” says Dan Jaffee, President & CEO, Oil-Dri Corporation of America. Jaffee also serves as President and General Manager of Amlan, which is the animal health business of Oil-Dri Corporation. “Vietnam is a vital producer of poultry and swine, and Nguyen will strengthen our operations there and will be a valuable asset in driving success for our producer customers in that country.”

Company Information
Amlan is the animal health business of Oil-Dri Corporation of America, leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact
press@amlan.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c79f14bd-bc5d-457b-9434-3920ea2ecbd7